ACTengine® IMA203 | Search

Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

21,278 results for “ACTengine® IMA203”

Trials

View all 17619 →

ACTengine® IMA203 Combined With mRNA-4203

15 participants · First posted Apr 27, 2025

SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma

360 participants · First posted Dec 19, 2024

ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors

375 participants · First posted Sep 26, 2018

Drugs

View all 1010 →

X-Synergy®

NanoLithium® NP03

Integra®-SC

Organizations

GENOMIC HEALTH, INC.

United States

Theralase Technologies Inc

Canada

Antengene Biologics Limited

Hong Kong, China

News

View all 2643 →

Immatics Announces Positive Clinical Data and Financial Update for Q3 2024

Immatics' IMA203 Demonstrates Promising Efficacy and Safety in Melanoma Phase 1 Trial

PRAME-Targeted T-Cell Therapy IMA203 Shows Promise in Metastatic Melanoma

Page 1 of 2128